Amgen Inc.
AMGN
Unten findest du den Live-Kurs für Amgen Inc. (AMGN), einen 1-Jahres-Chart, 8 Indikatoren (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volumen) und einen Vergleichsmodus. Hinzufügen zum Portfolio, auf die Beobachtungsliste setzen oder einen Preisalarm einrichten — alles in einem.
Amgen Inc. (AMGN) ist ein in United States ansässiges Healthcare-Unternehmen. Tätig in der Branche Drug Manufacturers - General, beschäftigt rund 31,500 Mitarbeiter:innen. Im vergangenen Jahr bewegte sich AMGN zwischen 269.77 und 391.29 USD. Das Trailing-KGV liegt bei rund 25.51, die Marktkapitalisierung bei etwa 197.69B USD. Aktuell wirft die Aktie eine Dividendenrendite von 2.75 % ab.
- Prev close
- $371.58
- Volume (24h)
- $1.05B
- Market cap
- $197.69B
- Currency
- USD
Bewertung
45/ 100 · Gemischt
- Wert27
- Qualität83
- Momentum49
- Wachstum36
- Risiko50
- Dividende44
- Liquidität26
Komposit aus öffentlichen Marktdaten. Nur zur Information — keine Anlageberatung.
Trendprojektion
Wohin der jüngste Trend zeigt, wenn er sich fortsetzt.
- +5 Bars
- 368.725 +0.66%
- +20 Bars
- 372.1112 +1.59%
- +60 Bars
- 373.4295 +1.95%
- +120 Bars
- 373.478 +1.96%
Lineare Regressions-Fortschreibung — keine Vorhersage, keine Anlageberatung. ±1σ ≈ 68% · ±2σ ≈ 95%: ±0.0246 USD.
Interpretation
Die zusammengesetzten Signale wirken gemischt. Stärke: Qualität mit schwäche: bilanzliquidität. Kurs liegt im oberen Drittel der jüngsten Spanne, Trend zeigt nach oben.
Beschreibende Beobachtung — keine Anlageberatung.
Bewertungs-Aufschlüsselung
Die Rohwerte hinter jedem Pillar — so siehst du, was die zusammengesetzte Bewertung liest.
- Wert27/100
Wert wirkt fragil — getragen von KGV (25.51).
KGV:25.51KBV:21.51PEG:2.01 - Qualität83/100
Qualität wirkt stark — getragen von EK-Rendite (101.32%).
EK-Rendite:101.32%GK-Rendite:8.35%Nettomarge:20.96%Bruttomarge:71.44% - Momentum49/100
Momentum wirkt gemischt — getragen von 52-Wo. Veränderung (23.80%).
52-Wo. Veränderung:23.80% - Wachstum36/100
Wachstum wirkt schwach — getragen von Umsatzwachstum (5.80%).
Umsatzwachstum:5.80%EPS-Wachstum:4.40% - Risiko50/100
Risiko wirkt gemischt — getragen von Verschuldungsgrad (623.75).
Beta:0.4Verschuldungsgrad:623.75Leerverkaufsquote:2.39% - Dividende44/100
Dividende wirkt schwach — getragen von Ausschüttungsquote (67.22%).
Dividendenrendite:2.75%Ausschüttungsquote:67.22% - Liquidität26/100
Liquidität wirkt fragil — getragen von Liquidität 3. Grades (1.26).
Liquidität 3. Grades:1.26Liquidität 2. Grades:0.85
Abgeleitet aus öffentlichen Marktdaten — informativ, keine Anlageberatung.
Referenzniveaus
Fibonacci-Retracements und -Extensions im jüngsten Bereich.
Nur Referenz — keine Anlageberatung.
Diese Koordinaten beschreiben Preisballungen aus der Vergangenheit, nicht wo gekauft oder verkauft werden sollte. Recherchiere selbst, bevor du handelst.
- ResistanceFib-Extension +161.8%472.4164 USD+28.97% vom aktuellen Kurs
- ResistanceFib-Extension +100%436.56 USD+19.18% vom aktuellen Kurs
- ResistanceFib-Extension +61.8%414.3964 USD+13.13% vom aktuellen Kurs
- ResistanceFib-Extension +27.2%394.3215 USD+7.65% vom aktuellen Kurs
- Aktuell366.29 USD
- SupportFib-Retracement 23.6%364.8473 USD-0.39% vom aktuellen Kurs
- SupportFib-Retracement 38.2%356.3764 USD-2.71% vom aktuellen Kurs
- SupportFib 50% Mittelpunkt349.53 USD-4.58% vom aktuellen Kurs
- SupportFib-Retracement 61.8%342.6836 USD-6.44% vom aktuellen Kurs
- SupportFib-Retracement 78.6%332.9363 USD-9.11% vom aktuellen Kurs
- SupportFib-Extension −27.2%304.7385 USD-16.80% vom aktuellen Kurs
- SupportFib-Extension −61.8%284.6636 USD-22.28% vom aktuellen Kurs
- SupportFib-Extension −100%262.5 USD-28.34% vom aktuellen Kurs
Financials
- 52w high
- $391.29
- 52w low
- $269.77
- 52w change
- 23.80%
- Day high
- $378.54
- Day low
- $361.74
- P/E (TTM)
- 25.51
- Forward P/E
- 15.62
- PEG
- 2.01
- Price / Book
- 21.51
- Beta (5Y)
- 0.4
- Enterprise value
- 242.97B
- EV / Revenue
- 6.53
- EV / EBITDA
- 14.36
- EPS (TTM)
- $14.36
- Forward EPS
- $23.45
- Dividend yield
- 2.75%
- Dividend rate
- $10.08
- Payout ratio
- 67.22%
- Revenue (TTM)
- 37.22B
- EBITDA
- 16.92B
- Free cash flow
- 7.44B
- Total cash
- 12.04B
- Total debt
- 57.32B
- Debt / Equity
- 623.75
- Current ratio
- 1.26
- Quick ratio
- 0.85
- Profit margin
- 20.96%
- Gross margin
- 71.44%
- Return on assets
- 8.35%
- Return on equity
- 101.32%
- Shares outstanding
- 539.71M
- Float
- 538.22M
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Analyst & Risk
- Beta (vs S&P 500)
- 0.4
- very stable
- 52-week change
- 23.80%
- Short % of float
- 2.39%
- Short ratio (days)
- 4.09
- Debt / Equity
- 623.75
- very high leverage
- Current ratio
- 1.26
- Quick ratio
- 0.85
- ROE
- 101.32%
- ROA
- 8.35%
- PEG ratio
- 2.01
- richly valued
- EV / Revenue
- 6.53
- EV / EBITDA
- 14.36
- Revenue growth
- 5.80%
- Earnings growth
- 4.40%
- EBITDA
- 16.92B
- Free cash flow
- 7.44B
- Total cash
- 12.04B
- Total debt
- 57.32B
- Insider holdings
- 0.22%
- Institutional
- 86.52%
Recent rating changes
- 2026-07-13UBSBuy → Buymain
- 2026-07-13GuggenheimNeutral → Neutralmain
- 2026-07-08Morgan StanleyEqual-Weight → Equal-Weightmain
- 2026-07-07Truist SecuritiesHold → Holdmain
- 2026-07-06Cantor FitzgeraldNeutral → Neutralreit
- 2026-06-16MizuhoNeutral → Neutralmain
- 2026-06-10Morgan StanleyEqual-Weight → Equal-Weightmain
- 2026-05-14Piper SandlerOverweight → Overweightmain
Financial documents
- Annual report of employee stock purchase11-K2026-06-11
- Corporate Changes & Voting Matters8-K2026-05-20
- Corporate Changes & Voting Matters8-K2026-05-19
- Periodic Financial Reports10-Q2026-05-01
- Corporate Changes & Voting Matters8-K2026-04-30
- Corporate Changes & Voting Matters8-K2026-04-22
- Proxy StatementsDEFA14A2026-04-21
- Proxy StatementsDEFA14A2026-04-15
- Proxy StatementsDEF 14A2026-04-07
- Annual Report to ShareholdersARS2026-03-31
- Corporate Changes & Voting Matters8-K2026-02-19
- Periodic Financial Reports10-K2026-02-13
Aktuelle Nachrichten
- Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market?Motley Fool2h ago
- What Comes After Merck’s Keytruda? The Race for the Next Standard Cancer Treatment.Barrons.com3h ago
- IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now?Motley Fool22h ago
- IXJ vs. IBBQ: Global Healthcare vs. Biotech -- Which ETF Is the Better Buy?Motley Fool1d ago
- The First Oral Cholesterol Pill Is Here. Which of These 5 Stocks Benefits Most?24/7 Wall St.2d ago
- Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?Zacks3d ago
- MRK Stock Jumps on FDA Nod for Cholesterol-Lowering PillZacks2d ago
- Seagate Stock And The Bet On A Denser FutureTrefis2d ago
Verwandt
Weitere Assets in dieser Kategorie.
- 8306.TMitsubishi UFJ Financial Group, Inc.3,473 USD-4.30%
- 7203.TToyota Motor Corporation2,899.5 USD-0.33%
- 9984.TSoftBank Group Corp.5,424 USD-9.01%
- 6758.TSony Group Corporation3,470 USD+0.93%
- 6861.TKeyence Corporation70,880 USD-4.28%
- NVDANVIDIA Corporation202.81 USD-2.21%
- AAPLApple Inc.333.74 USD+0.14%
- 0700.HKTencent Holdings Limited477.8 USD+3.51%
Live-Diskussion
Anmelden to join the discussion.
- Noch keine Kommentare. Sei der Erste.